Status and phase
Conditions
Treatments
About
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic control with empaglyflozin 25 mg and metformin
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
208 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
SeJin Kim
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal